These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 23774148)

  • 41. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients.
    Park HS; Lee JK; Kim DW; Kulig K; Kim TM; Lee SH; Jeon YK; Chung DH; Heo DS
    Lung Cancer; 2012 Aug; 77(2):288-92. PubMed ID: 22465695
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Future options for ALK-positive non-small cell lung cancer.
    Iacono D; Chiari R; Metro G; Bennati C; Bellezza G; Cenci M; Ricciuti B; Sidoni A; Baglivo S; Minotti V; Crinò L
    Lung Cancer; 2015 Mar; 87(3):211-9. PubMed ID: 25601484
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement.
    Schwab R; Petak I; Kollar M; Pinter F; Varkondi E; Kohanka A; Barti-Juhasz H; Schönleber J; Brauswetter D; Kopper L; Urban L
    Lung Cancer; 2014 Jan; 83(1):109-11. PubMed ID: 24192513
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors.
    Ceccon M; Mologni L; Bisson W; Scapozza L; Gambacorti-Passerini C
    Mol Cancer Res; 2013 Feb; 11(2):122-32. PubMed ID: 23239810
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer.
    Ou SH
    Expert Rev Anticancer Ther; 2012 Feb; 12(2):151-62. PubMed ID: 22316363
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib.
    Brosnan EM; Weickhardt AJ; Lu X; Maxon DA; Barón AE; Chonchol M; Camidge DR
    Cancer; 2014 Mar; 120(5):664-74. PubMed ID: 24258622
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of Renal Function on Crizotinib Pharmacokinetics: Dose Recommendations for Patients with ALK-Positive Non-Small Cell Lung Cancer.
    Tan W; Yamazaki S; Johnson TR; Wang R; O'Gorman MT; Kirkovsky L; Boutros T; Brega NM; Bello A
    Clin Drug Investig; 2017 Apr; 37(4):363-373. PubMed ID: 28035616
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic options.
    Lazzari C; Spitaleri G; Catania C; Barberis M; Noberasco C; Santarpia M; Delmonte A; Toffalorio F; Conforti F; De Pas TM
    Crit Rev Oncol Hematol; 2014 Mar; 89(3):358-65. PubMed ID: 24156959
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Response to chemotherapy, reexposure to crizotinib and treatment with a novel ALK inhibitor in a patient with acquired crizotinib resistance.
    Schrödl K; von Schilling C; Tufman A; Huber RM; Gamarra F
    Respiration; 2014; 88(3):262-4. PubMed ID: 25115320
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer.
    D'Arcangelo M; Wynes MW; Hirsch FR
    Curr Opin Oncol; 2013 Mar; 25(2):121-9. PubMed ID: 23385859
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase.
    Yamazaki S; Lam JL; Zou HY; Wang H; Smeal T; Vicini P
    Drug Metab Dispos; 2015 Jan; 43(1):54-62. PubMed ID: 25349124
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.
    Kodama T; Tsukaguchi T; Yoshida M; Kondoh O; Sakamoto H
    Cancer Lett; 2014 Sep; 351(2):215-21. PubMed ID: 24887559
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH.
    Minca EC; Portier BP; Wang Z; Lanigan C; Farver CF; Feng Y; Ma PC; Arrossi VA; Pennell NA; Tubbs RR
    J Mol Diagn; 2013 May; 15(3):341-6. PubMed ID: 23499337
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical Implications of Variant ALK FISH Rearrangement Patterns.
    Gao X; Sholl LM; Nishino M; Heng JC; Jänne PA; Oxnard GR
    J Thorac Oncol; 2015 Nov; 10(11):1648-52. PubMed ID: 26536196
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ceritinib for treatment of ALK-rearranged advanced non-small-cell lung cancer.
    Vansteenkiste JF
    Future Oncol; 2014 Oct; 10(12):1925-39. PubMed ID: 24856155
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The next-generation ALK inhibitors.
    Pall G
    Curr Opin Oncol; 2015 Mar; 27(2):118-24. PubMed ID: 25588040
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pulsatile crizotinib treatment for brain metastasis in a patient with non-small-cell lung cancer.
    Wang S; Chen J; Xie Z; Xia L; Luo W; Li J; Li Q; Yang Z
    J Clin Pharm Ther; 2017 Oct; 42(5):627-630. PubMed ID: 28667686
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effective Crizotinib schedule for an elderly patient with ALK rearranged non-small-cell lung cancer: a case report.
    Fukuizumi A; Miyanaga A; Seike M; Kato Y; Nakamichi S; Chubachi K; Matsumoto M; Noro R; Minegishi Y; Kunugi S; Kubota K; Gemma A
    BMC Res Notes; 2015 Apr; 8():165. PubMed ID: 25899913
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Circulating Tumor Cells with Aberrant
    Pailler E; Oulhen M; Borget I; Remon J; Ross K; Auger N; Billiot F; Ngo Camus M; Commo F; Lindsay CR; Planchard D; Soria JC; Besse B; Farace F
    Cancer Res; 2017 May; 77(9):2222-2230. PubMed ID: 28461563
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Successful crizotinib rechallenge after crizotinib-induced interstitial lung disease in patients with advanced non-small-cell lung cancer.
    Asai N; Yamaguchi E; Kubo A
    Clin Lung Cancer; 2014 May; 15(3):e33-5. PubMed ID: 24702855
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.